The Promise and Pitfalls of Polygenic Risk Scores in Healthcare

Polygenic risk scores (PRS) represent a significant advancement in genetic research, providing a numerical estimate of an individual's genetic predisposition to complex diseases by aggregating the effects of numerous genetic variants. Dr. Anna CF Lewis, a bioethicist at Harvard Medical School, explains that these scores are calculated by weighing the contributions of many single-nucleotide variants linked to specific diseases, such as coronary artery disease. This approach contrasts with traditional genetic tests that focus on single mutations.

Technology Networks

The integration of PRS into healthcare holds the potential to personalize medical interventions and preventive strategies. By identifying individuals at higher genetic risk for conditions like heart disease or diabetes, healthcare providers can implement earlier lifestyle changes, screenings, or preventive treatments. Recent research presented at the American Heart Association Conference 2025 indicates that incorporating PRS into cardiovascular disease (CVD) risk prediction tools, such as the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT), can significantly enhance predictive accuracy across diverse populations. This improvement could lead to better identification of high-risk individuals, potentially saving lives and improving overall population health.

Researchers Find Polygenic Risk Scores Improve Accuracy of CVD Risk PredictionTechnology Networks

Despite the promising applications of PRS, their integration into routine healthcare raises several ethical and practical concerns. One major issue is the potential for genetic discrimination, where individuals may face biases based on their genetic risk profiles. Additionally, the use of PRS in embryo selection raises profound ethical questions about reproductive choices and societal pressures toward "genetic optimization." Dr. Lewis cautions against genetic fatalism, the belief that genes rigidly determine health outcomes, emphasizing the need for ethical reflection as scientific tools evolve.

Technology Networks

Dr. Lewis noted, “It is hoped that polygenic risk scores can identify the most effective ways to incorporate their use into healthcare,” while acknowledging that research is ongoing to validate these hopes. The findings from Genomics, a science-led techbio company, support the implementation of PRS in clinical settings, highlighting that over three million individuals aged 40-70 in the U.S. are currently at high risk of CVD but remain undetected due to the lack of genetic information in risk assessments.

Researchers Find Polygenic Risk Scores Improve Accuracy of CVD Risk Prediction

Critics argue that the reliance on PRS could lead to oversimplification of complex health issues, potentially neglecting environmental and lifestyle factors that also contribute to disease risk. There are concerns that without careful evaluation of the predictive power and fairness of PRS, their promise may remain largely theoretical.

Researchers Find Polygenic Risk Scores Improve Accuracy of CVD Risk Prediction

As the field of genomics continues to advance, the ethical landscape surrounding PRS will evolve. Proactive engagement, transparency, and careful policy development will be essential to ensure that these scores enhance individual and societal well-being rather than limit it. The NHS's recent commitment to rolling out prevention strategies based on PRS across the country signifies a step toward integrating genetic insights into mainstream healthcare.

Technology Networks

“Our findings show that incorporating polygenic risk scores into clinical practice can significantly improve the predictive power of tools like PREVENT across diverse populations, making risk assessment more equitable and precise.” — Professor Sir Peter Donnelly, Co-Founder and CEO of Genomics.

Researchers Find Polygenic Risk Scores Improve Accuracy of CVD Risk Prediction

“Without this, the promise of polygenic risk scores remain largely theoretical.” — Dr. Anna CF Lewis, Bioethicist, Harvard Medical School.

Technology Networks